# Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

> **NCT00305708** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 40 (estimated)

## Conditions studied

- Congenital Amegakaryocytic Thrombocytopenia
- Diamond-blackfan Anemia
- Fanconi Anemia
- Leukemia
- Severe Congenital Neutropenia
- Thrombocytopenia

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** busulfan
- **DRUG:** fludarabine phosphate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** umbilical cord blood transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00305708
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305708, "Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00305708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*